Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer

BACKGROUND: Canfosfamide is a novel glutathione analog activated by glutathione S-transferase P1-1. This study evaluated the safety and efficacy of canfosfamide in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum resistant ovarian cancer. Patients with platinum resist...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Kavanagh, John J, Levenback, Charles F, Ramirez, Pedro T, Wolf, Judith L, Moore, Carla L, Jones, Marsha R, Meng, Lisa, Brown, Gail L, Bast, Robert C
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2010
Onderwerpen:
Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2851575/
https://ncbi.nlm.nih.gov/pubmed/20222977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-3-9
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items